The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Arena Pharmaceuticals competitive analysis

Loading summary...

Latest patents of Arena Pharmaceuticals opposed by its competitors

Explore Arena Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3242666
Dec 25, 2024Methods Of Treating Conditions Related To The S1P1 Receptor4
EP3801459
Aug 7, 2024Methods Of Treating Conditions Related To The S1P1 Receptor4
EP3582814
May 1, 2024Compounds And Methods For Treatment Of Inflammatory Bowel Disease With Extra-Intestinal Manifestations2
EP3860590
Jun 7, 2023Methods For The Treatment Of Scleroderma3
EP3310760
Oct 19, 2022Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated Disorders2

Latest PTAB cases involving Arena Pharmaceuticals

Discover the latest PTAB cases involving Arena Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Arena Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ARENA PHARMACEUTICALS - 15 - -
MAIWALD136 - - -
SANDOZ1191619 -
TEVA PHARMACEUTICALS20916 - 12